+

WO2013167995A3 - Compositions et méthodes de traitement de l'hyperglycémie - Google Patents

Compositions et méthodes de traitement de l'hyperglycémie Download PDF

Info

Publication number
WO2013167995A3
WO2013167995A3 PCT/IB2013/050903 IB2013050903W WO2013167995A3 WO 2013167995 A3 WO2013167995 A3 WO 2013167995A3 IB 2013050903 W IB2013050903 W IB 2013050903W WO 2013167995 A3 WO2013167995 A3 WO 2013167995A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
complications
treatment
hyperglycemia
compositions
Prior art date
Application number
PCT/IB2013/050903
Other languages
English (en)
Other versions
WO2013167995A2 (fr
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Priority to JP2015510897A priority Critical patent/JP2016510306A/ja
Priority to CA2873087A priority patent/CA2873087A1/fr
Priority to CN201380030654.2A priority patent/CN104812737A/zh
Priority to AU2013257716A priority patent/AU2013257716A1/en
Priority to SG11201407316QA priority patent/SG11201407316QA/en
Publication of WO2013167995A2 publication Critical patent/WO2013167995A2/fr
Publication of WO2013167995A3 publication Critical patent/WO2013167995A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés de formule I ou leurs sels pharmaceutiquement acceptables, ainsi que leurs formes polymorphes, leurs solvates, leurs énantiomères, leurs stéréoisomères et leurs hydrates. Elle concerne des compositions pharmaceutiques comprenant une quantité efficace de composés de formule I; et des méthodes de traitement de l'hyperglycémie. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, muqueuse, intraveineuse, parentérale, sous forme de sirop ou d'injection. Ces compositions peuvent être utilisées pour traiter la résistance à l'insuline, le diabète sucré, le diabète insipide, le diabète de type 1, le diabète de type 2, les complications microvasculaires, les complications macrovasculaires, les troubles lipidiques, le prédiabète, l'obésité, l'arythmie, l'infarctus du myocarde, l'accident vasculaire cérébral, la neuropathie, les complications rénales, l'hypertriglycéridémie, les complications cardiovasculaires, et l'hyperglycémie post-prandiale.
PCT/IB2013/050903 2012-05-08 2013-02-03 Compositions et méthodes de traitement de l'hyperglycémie WO2013167995A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2015510897A JP2016510306A (ja) 2012-05-08 2013-02-03 高血糖の治療のための組成物及び方法
CA2873087A CA2873087A1 (fr) 2012-05-08 2013-02-03 Compositions et methodes de traitement de l'hyperglycemie
CN201380030654.2A CN104812737A (zh) 2012-05-08 2013-02-03 用于治疗高血糖症的组合物和方法
AU2013257716A AU2013257716A1 (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia
SG11201407316QA SG11201407316QA (en) 2012-05-08 2013-02-03 Compositions and methods for the treatment of hyperglycemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1811/CHE/2012 2012-05-08
IN1811CH2012 2012-05-08

Publications (2)

Publication Number Publication Date
WO2013167995A2 WO2013167995A2 (fr) 2013-11-14
WO2013167995A3 true WO2013167995A3 (fr) 2016-09-01

Family

ID=54193690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050903 WO2013167995A2 (fr) 2012-05-08 2013-02-03 Compositions et méthodes de traitement de l'hyperglycémie

Country Status (6)

Country Link
JP (1) JP2016510306A (fr)
CN (1) CN104812737A (fr)
AU (1) AU2013257716A1 (fr)
CA (1) CA2873087A1 (fr)
SG (1) SG11201407316QA (fr)
WO (1) WO2013167995A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198971A1 (fr) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions et méthodes de traitement de l'hyperglycémie et du syndrome métabolique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO2004007524A2 (fr) * 2002-07-17 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oligopeptides bicycliques
EP1903034A1 (fr) * 2006-09-19 2008-03-26 Technische Universität Graz Iminosucres glycoconjugués

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
JPS5283951A (en) * 1976-01-01 1977-07-13 Nippon Shinyaku Co Ltd Remedy for hyperglycemia and depressant for lipid-biosythesis
JPS5943946B2 (ja) * 1978-04-28 1984-10-25 日本新薬株式会社 Ｎ−アルケニルモラノリン誘導体
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
JPH01308229A (ja) * 1988-02-23 1989-12-12 Glaxo Group Ltd 複素環誘導体
JPH06329671A (ja) * 1993-05-21 1994-11-29 Tsumura & Co 新規アルカロイド及びその用途
EP1879578A4 (fr) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc Methodes et compositions destinees au traitement de l'incontinence urinaire
CN101129476B (zh) * 2006-08-21 2013-07-24 中国医学科学院药物研究所 桑枝生物碱有效部位在制备降血糖药物中的应用
EP2152276A4 (fr) * 2007-05-09 2011-09-14 Traffick Therapeutics Inc Dosage de criblage pour identifier des correcteurs de défauts de trafic des protéines
GB0809360D0 (en) * 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
US20110237538A1 (en) * 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20110172240A1 (en) * 2010-01-08 2011-07-14 Milne Jill C Fatty acid fumarate derivatives and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643874A (en) * 1993-08-05 1997-07-01 Hoffmann-La Roche Inc. Pharmaceutical composition comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO2004007524A2 (fr) * 2002-07-17 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oligopeptides bicycliques
EP1903034A1 (fr) * 2006-09-19 2008-03-26 Technische Universität Graz Iminosucres glycoconjugués

Also Published As

Publication number Publication date
JP2016510306A (ja) 2016-04-07
AU2013257716A1 (en) 2014-11-27
SG11201407316QA (en) 2014-12-30
WO2013167995A2 (fr) 2013-11-14
CA2873087A1 (fr) 2013-11-14
CN104812737A (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
WO2014087307A3 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2010018549A3 (fr) Compositions thérapeutiques contenant du macitentan
WO2013175377A3 (fr) Compositions et méthodes pour le traitement de la mucosite
MX365108B (es) Derivados piperidina para agonista gpr119.
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2016046680A3 (fr) Compositions et procédés de traitement de maladies métaboliques hépatiques
WO2008098978A3 (fr) Composés de benzofurane
WO2014174425A3 (fr) Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques
WO2014091384A3 (fr) Compositions et méthodes pour le traitement de la mucosite
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014080307A3 (fr) Compositions et procédés pour le traitement du diabète et du pré-diabète
WO2014106804A3 (fr) Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2013167995A3 (fr) Compositions et méthodes de traitement de l'hyperglycémie
WO2012011707A3 (fr) Dérivés de pyridinone substituée et leurs procédés de fabrication
WO2014195810A3 (fr) Compositions et méthodes pour le traitement du diabète et du prédiabète
WO2013167998A3 (fr) Compositions et méthodes de traitement de troubles autonomiques et autres troubles neurologiques
WO2013167997A3 (fr) Compositions et méthodes de traitement du syndrome métabolique
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014122575A3 (fr) Conjugués d'acide gras pour le traitement d'inflammations et de maladies métaboliques
WO2013175344A3 (fr) Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2014083476A3 (fr) Compositions et méthodes pour le traitement de troubles métaboliques et lipidiques
WO2014068461A3 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
WO2015015403A3 (fr) Compositions et méthodes utilisables en vue du traitement du diabète et du pré-diabète
WO2014068459A3 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2873087

Country of ref document: CA

Ref document number: 2015510897

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013787060

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257716

Country of ref document: AU

Date of ref document: 20130203

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载